HCV kinetics by the two different real-time HCV assays in DAA-based treatment

HCV kinetics by the two different real-time HCV assays in DAA-based treatment - Viral kinetics in DAA-based treatment

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000023115

Enrollment

250

Registered

2016-07-11

Start date

2015-08-03

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic hepatitis C

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Eligible patients were aged 20 years and older with confirmed chronic HCV mono-infection.

Exclusion criteria

Exclusion criteria: Exclusion criteria included positivity for antibody to human immunodeficiency virus or positivity for hepatitis B surface antigen, clinical or biochemical evidence of hepatic decompensation, and any non-HCV related liver disease,such as autoimmune hepatitis or primary biliary cirrhosis.

Design outcomes

Primary

Measure	Time frame
Association between HCV kinetics by TaqMan and AccuGene assays and treatment outcome in DAA-based treatment	—

Countries

Japan

Contacts

Public ContactEiichi Ogawa

Kyushu University Hospital Department of General Internal Medicine

eogawa@gim.med.kyushu-u.ac.jp092-642-5909

Outcome results